Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The analysis of investment activity ratios reveals a divergence between the utilization of fixed assets and the efficiency of total asset and equity employment over the five-year period ending December 31, 2023.
- Fixed Asset Utilization
- A consistent downward trend is observed in both measures of fixed asset turnover. The net fixed asset turnover declined from 3.23 in 2019 to 2.66 in 2023, while the ratio including right-of-use assets dropped from 2.94 to 2.48 over the same period. Although a temporary recovery occurred in 2021, the subsequent declines in 2022 and 2023 suggest that the growth in fixed asset investment has outpaced the growth in generated revenue, resulting in lower asset productivity.
- Total Asset Efficiency
- In contrast to fixed assets, the total asset turnover remained relatively stable with a slight upward trajectory toward the end of the period. The ratio fluctuated between 0.49 and 0.60, reaching its peak of 0.60 in 2023. This stability indicates that the company has maintained a consistent ability to generate sales from its overall asset base, offsetting the declining efficiency observed in specific long-term fixed assets.
- Equity Turnover
- Equity turnover experienced a significant contraction between 2019 and 2020, falling from 2.31 to 1.77. Since 2020, the ratio has remained largely stagnant, ending at 1.71 in 2023. This pattern suggests a decrease in the efficiency of generating revenue relative to shareholder equity, which may be attributed to an increase in the equity base that has not been matched by a proportional increase in top-line growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Fixed Asset Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Property, plant and equipment including finance lease right of use assets, less accumulated depreciation | 3,213) | 2,753) | 2,422) | 2,202) | 1,940) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 2.66 | 2.93 | 3.21 | 3.03 | 3.23 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 10.89 | 11.76 | 11.00 | — | — | |
| Amgen Inc. | 4.53 | 4.57 | 4.69 | — | — | |
| Bristol-Myers Squibb Co. | 6.77 | 7.38 | 7.67 | — | — | |
| Danaher Corp. | 5.25 | 7.96 | 7.77 | — | — | |
| Eli Lilly & Co. | 2.64 | 2.81 | 3.15 | — | — | |
| Gilead Sciences Inc. | 5.07 | 4.93 | 5.27 | — | — | |
| Johnson & Johnson | 4.28 | 4.79 | 4.95 | — | — | |
| Merck & Co. Inc. | 2.61 | 2.77 | 2.53 | — | — | |
| Pfizer Inc. | 3.14 | 6.22 | 5.52 | — | — | |
| Regeneron Pharmaceuticals Inc. | 3.16 | 3.23 | 4.62 | — | — | |
| Thermo Fisher Scientific Inc. | 4.54 | 4.84 | 4.71 | — | — | |
| Vertex Pharmaceuticals Inc. | 8.51 | 8.06 | 6.92 | — | — | |
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.12 | 4.98 | 4.98 | — | — | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | 7.22 | 7.88 | 7.74 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Net fixed asset turnover = Revenue ÷ Property, plant and equipment including finance lease right of use assets, less accumulated depreciation
= 8,544 ÷ 3,213 = 2.66
2 Click competitor name to see calculations.
Analysis of the five-year period from 2019 to 2023 reveals a consistent increase in total revenue alongside an aggressive expansion of the company's fixed asset base. While revenue grew steadily, the rate of investment in property, plant, and equipment exceeded the rate of revenue growth, resulting in a gradual decline in asset utilization efficiency.
- Revenue Trajectory
- Revenue demonstrated a continuous upward trend, increasing from US$ 6,260 million in 2019 to US$ 8,544 million by the end of 2023. This represents a steady and uninterrupted expansion of the top line over the observed period.
- Net Fixed Asset Expansion
- Net property, plant, and equipment, including finance lease right-of-use assets, experienced significant growth, rising from US$ 1,940 million in 2019 to US$ 3,213 million in 2023. The investment in the asset base accelerated toward the end of the period, with a notable increase between 2022 and 2023.
- Net Fixed Asset Turnover Efficiency
- The net fixed asset turnover ratio shifted from 3.23 in 2019 to 2.66 in 2023. Despite a temporary recovery to 3.21 in 2021, the ratio has since followed a downward trajectory. This decline indicates that the company is generating progressively less revenue per unit of net fixed assets, suggesting that the scale of capital investment has outpaced the immediate generation of corresponding sales.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Zoetis Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Property, plant and equipment including finance lease right of use assets, less accumulated depreciation | 3,213) | 2,753) | 2,422) | 2,202) | 1,940) | |
| Operating lease right of use assets | 230) | 220) | 181) | 192) | 189) | |
| Property, plant and equipment including finance lease right of use assets, less accumulated depreciation (including operating lease, right-of-use asset) | 3,443) | 2,973) | 2,603) | 2,394) | 2,129) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.48 | 2.72 | 2.99 | 2.79 | 2.94 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | 9.47 | 10.24 | 9.57 | — | — | |
| Amgen Inc. | 4.08 | 4.13 | 4.23 | — | — | |
| Bristol-Myers Squibb Co. | 5.60 | 6.18 | 6.66 | — | — | |
| Danaher Corp. | 4.26 | 6.35 | 6.10 | — | — | |
| Eli Lilly & Co. | 2.45 | 2.63 | 2.93 | — | — | |
| Gilead Sciences Inc. | 4.57 | 4.51 | 4.77 | — | — | |
| Johnson & Johnson | 4.07 | 4.54 | 4.72 | — | — | |
| Merck & Co. Inc. | 2.45 | 2.60 | 2.33 | — | — | |
| Pfizer Inc. | 2.72 | 5.25 | 4.64 | — | — | |
| Regeneron Pharmaceuticals Inc. | 3.11 | 3.17 | 4.52 | — | — | |
| Thermo Fisher Scientific Inc. | 3.89 | 4.13 | 3.98 | — | — | |
| Vertex Pharmaceuticals Inc. | 6.79 | 6.13 | 5.32 | — | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.71 | 4.48 | 4.45 | — | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | 6.36 | 6.90 | 6.75 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property, plant and equipment including finance lease right of use assets, less accumulated depreciation (including operating lease, right-of-use asset)
= 8,544 ÷ 3,443 = 2.48
2 Click competitor name to see calculations.
The company demonstrates a steady increase in revenue and a corresponding growth in its net fixed asset base over the five-year period ending December 31, 2023. While total revenue rose from US$ 6,260 million in 2019 to US$ 8,544 million in 2023, the investment in property, plant, and equipment—including right-of-use assets—expanded more aggressively, rising from US$ 2,129 million to US$ 3,443 million.
- Revenue and Asset Growth Trends
- Revenue exhibited consistent growth throughout the period, resulting in a cumulative increase of approximately 36.5% between 2019 and 2023. During the same timeframe, net fixed assets increased by approximately 61.7%. This indicates that the expansion of the fixed asset base significantly outpaced the growth of top-line revenue.
- Net Fixed Asset Turnover Analysis
- The net fixed asset turnover ratio shows an overall downward trajectory, moving from 2.94 in 2019 to 2.48 in 2023. Although a temporary peak of 2.99 was reached in 2021, the ratio declined steadily in the subsequent two years. This pattern suggests a decrease in the efficiency with which the company utilizes its long-term physical assets to generate sales.
- Operational Efficiency Insights
- The decline in the turnover ratio from 2.99 in 2021 to 2.48 in 2023 highlights a growing gap between asset accumulation and revenue realization. The data suggests that recent investments in property, plant, and equipment have not yet translated into proportional revenue gains, which is often characteristic of a capacity expansion phase where assets are deployed before reaching full operational productivity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Total Asset Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Total assets | 14,286) | 14,925) | 13,900) | 13,609) | 11,545) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.60 | 0.54 | 0.56 | 0.49 | 0.54 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 0.40 | 0.42 | 0.38 | — | — | |
| Amgen Inc. | 0.28 | 0.38 | 0.40 | — | — | |
| Bristol-Myers Squibb Co. | 0.47 | 0.48 | 0.42 | — | — | |
| Danaher Corp. | 0.28 | 0.37 | 0.35 | — | — | |
| Eli Lilly & Co. | 0.53 | 0.58 | 0.58 | — | — | |
| Gilead Sciences Inc. | 0.43 | 0.43 | 0.40 | — | — | |
| Johnson & Johnson | 0.51 | 0.51 | 0.52 | — | — | |
| Merck & Co. Inc. | 0.56 | 0.54 | 0.46 | — | — | |
| Pfizer Inc. | 0.26 | 0.51 | 0.45 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.40 | 0.42 | 0.63 | — | — | |
| Thermo Fisher Scientific Inc. | 0.43 | 0.46 | 0.41 | — | — | |
| Vertex Pharmaceuticals Inc. | 0.43 | 0.49 | 0.56 | — | — | |
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.40 | 0.47 | 0.45 | — | — | |
| Total Asset Turnover, Industry | ||||||
| Health Care | 0.63 | 0.66 | 0.62 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Total asset turnover = Revenue ÷ Total assets
= 8,544 ÷ 14,286 = 0.60
2 Click competitor name to see calculations.
The analysis of investment activity between 2019 and 2023 reveals a sustained expansion in revenue coupled with a fluctuating asset base, leading to an overall improvement in asset utilization efficiency by the end of the period.
- Revenue Trajectory
- Revenue demonstrated consistent year-over-year growth, increasing from US$ 6,260 million in 2019 to US$ 8,544 million in 2023. This upward trend indicates a steady expansion in market reach or pricing power throughout the analyzed timeframe.
- Asset Base Evolution
- Total assets grew significantly between 2019 and 2022, rising from US$ 11,545 million to a peak of US$ 14,925 million. A contraction was observed in 2023, with assets decreasing to US$ 14,286 million, suggesting a shift toward asset optimization or a reduction in capital expenditure.
- Total Asset Turnover Performance
- The total asset turnover ratio experienced volatility, reaching a period low of 0.49 in 2020 before recovering. The ratio peaked at 0.60 in 2023, the highest value in the five-year sequence. The improvement in 2023 is particularly notable as it resulted from the convergence of rising revenues and a reduced asset base, signaling an increase in the efficiency with which the company generates sales from its investments.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Equity Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Total Zoetis Inc. equity | 4,997) | 4,405) | 4,543) | 3,769) | 2,708) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 1.71 | 1.83 | 1.71 | 1.77 | 2.31 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.24 | 3.36 | 3.65 | — | — | |
| Amgen Inc. | 4.32 | 6.77 | 3.63 | — | — | |
| Bristol-Myers Squibb Co. | 1.53 | 1.49 | 1.29 | — | — | |
| Danaher Corp. | 0.45 | 0.63 | 0.65 | — | — | |
| Eli Lilly & Co. | 3.17 | 2.68 | 3.15 | — | — | |
| Gilead Sciences Inc. | 1.18 | 1.27 | 1.28 | — | — | |
| Johnson & Johnson | 1.24 | 1.24 | 1.27 | — | — | |
| Merck & Co. Inc. | 1.60 | 1.29 | 1.28 | — | — | |
| Pfizer Inc. | 0.67 | 1.06 | 1.06 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.51 | 0.54 | 0.86 | — | — | |
| Thermo Fisher Scientific Inc. | 0.92 | 1.02 | 0.96 | — | — | |
| Vertex Pharmaceuticals Inc. | 0.56 | 0.64 | 0.75 | — | — | |
| Equity Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 1.15 | 1.24 | 1.27 | — | — | |
| Equity Turnover, Industry | ||||||
| Health Care | 1.69 | 1.69 | 1.67 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Equity turnover = Revenue ÷ Total Zoetis Inc. equity
= 8,544 ÷ 4,997 = 1.71
2 Click competitor name to see calculations.
Analysis of the financial performance between 2019 and 2023 indicates a steady increase in revenue alongside a general expansion of the equity base. While top-line growth remained consistent, the equity turnover ratio experienced an initial contraction followed by a period of relative stabilization.
- Revenue Trends
- Revenue demonstrated a consistent upward trajectory, increasing from 6,260 million US$ in 2019 to 8,544 million US$ by 2023. This represents a continuous growth pattern in sales volume or pricing power over the five-year period.
- Equity Base Evolution
- Total equity grew significantly from 2,708 million US$ in 2019 to 4,997 million US$ in 2023. A slight contraction was observed in 2022, where equity decreased to 4,405 million US$ from 4,543 million US$ in the previous year, before rebounding to its highest level in 2023.
- Equity Turnover Analysis
- The equity turnover ratio saw a notable decline from 2.31 in 2019 to 1.71 in 2021. This downward trend indicates that the growth in total equity outpaced the growth in revenue during the early part of the period, resulting in a lower efficiency of equity utilization. Between 2021 and 2023, the ratio stabilized, fluctuating between 1.71 and 1.83, suggesting that the rate of revenue growth began to align more closely with the expansion of the equity base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?